Abstract: Described are new glycoprotein hormones capable of competing with natural hormones for the normal receptor binding sites but substantially incapable of effecting post receptor activities. The glycoprotein hormones of the present invention have had specific (rather than all) oligosaccharide chains removed so as to effectively diminish biologic activity while not significantly reducing plasma half-life, thus improving the molecules effectiveness as an antagonist compared with conventionally-produced molecules. The preferred glycoprotein hormones are ideally obtained by site-directed mutagenesis to selectively deglycosylate the protein. Also described are therapeutic treatments comprising the administration of the recombinant glycoprotein hormones of the present invention as hormone antagonists.
Type:
Grant
Filed:
May 16, 1995
Date of Patent:
June 3, 1997
Assignee:
Applied Research Systems ARS Holding N.V.
Abstract: A method of inhibiting the proliferation rate of hepatocytes in a subject by administering to the subject the free tripeptide of the composition SDK (serine-aspartic acid-lysine) or the salt thereof.